Skip to Main Content

Early last year, a former Valeant Pharmaceuticals (VRX) executive told Congress that, when the company took huge price hikes on two life-saving heart drugs in 2013, the drug maker believed the move “should not reduce patient access.”

He was wrong.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!